EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK ‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam

Hoang Gia Nguyen iD, Xuan Hau Nguyen, Phuong Nguyen iD, Thu Huong Nguyen iD, Quang Bui Vinh iD

Thoracic Cancer · 2026

DOI: 10.1111/1759-7714.70325 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Thoracic Cancer, 2026. Verfasst von Hoang Gia Nguyen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Lung and Breast Medical Oncology Department, Hanoi Oncology Hospital, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Brain Neoplasms, Carbazoles, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study compared the efficacy of first‐line alectinib versus ceritinib and evaluated the role of upfront brain radiotherapy (RT) in patients with ALK‐positive non‐small cell lung cancer (NSCLC) and brain metastases (BM).

Methods

We retrospectively analyzed 108 patients with ALK‐positive NSCLC and baseline BM treated with first‐line alectinib ( n = 42) or ceritinib ( n = 66) at two Vietnamese centers between 2019 and 2025. Intracranial and systemic responses were assessed by RANO‐BM and RECIST v1.1 criteria, respectively. Survival outcomes were analyzed using the Kaplan–Meier method and multivariable Cox regression.

Results

First‐line alectinib demonstrated superior intracranial disease control compared with ceritinib (iDCR 97.6% vs. 83.3%, p = 0.026; median iPFS 40.4 vs. 17.2 months, univariable HR 0.46, 95% CI 0.26–0.82, p = 0.005). Systemic PFS was also significantly longer with alectinib (35.9 vs. 11.5 months, univariable HR 0.38, 95% CI 0.22–0.65, p = 0.001). Exploratory subgroup analyses suggested differential effects of upfront brain RT by TKI, but interaction tests were non‐significant ( p = 0.642 for iPFS, p = 0.837 for systemic PFS). In multivariable analysis, alectinib remained an independent predictor of better iPFS (HR 0.38, 95% CI 0.20–0.70, p = 0.002) and systemic PFS (HR 0.34, 95% CI 0.20–0.59, p = 0.001). Grade ≥ 3 adverse events occurred in 19.0% of patients with alectinib versus 34.8% with ceritinib ( p = 0.068).

Conclusions

In this real‐world Vietnamese cohort, first‐line alectinib showed superior intracranial and systemic efficacy over ceritinib. In resource‐limited settings, ceritinib combined with upfront brain RT is a reasonable clinical alternative. The differential benefit of brain RT between the two TKIs remains hypothesis‐generating.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsCarbazolesCarcinoma, Non-Small-Cell LungLung NeoplasmsPiperidinesPyrimidinesSulfonesAdultAgedFemaleHumansMaleMiddle AgedAnaplastic Lymphoma KinaseProtein Kinase InhibitorsRetrospective StudiesVietnam

Stichwörter der Autor:innen

alectinibanaplastic lymphoma kinasebrain metastasescarcinomaceritinibnon‐small‐cell lung

Substanzen

alectinibALK protein, humanAnaplastic Lymphoma KinaseCarbazolesceritinibPiperidinesProtein Kinase InhibitorsPyrimidinesSulfones

Autor:innen und Institutionen

  • Lung and Breast Medical Oncology Department, Hanoi Oncology Hospital, Hanoi, Vietnam.
  • Department of Oncology, Hanoi Medical University, Hanoi, Vietnam.
  • Department of Medical Oncology, Vietnam National Cancer Hospital - K Hospital, Hanoi, Vietnam.
  • Department of Radiation Oncology, Hanoi Oncology Hospital, Hanoi, Vietnam.

ORCID-Profile: Hoang Gia Nguyen, Phuong Nguyen, Thu Huong Nguyen, Quang Bui Vinh

Zitieren

APA

Nguyen, H. G., Nguyen, X. H., Nguyen, P., Nguyen, T. H., & Vinh, Q. B. (2026). First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK ‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70325

Vancouver

Nguyen HG, Nguyen XH, Nguyen P, Nguyen TH, Vinh QB. First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK ‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam. Thoracic Cancer. 2026. doi:10.1111/1759-7714.70325

BibTeX
@article{Nguyen2026,
  author = {Nguyen, Hoang Gia and Nguyen, Xuan Hau and Nguyen, Phuong and Nguyen, Thu Huong and Vinh, Quang Bui},
  title = {First‐Line Alectinib Versus Ceritinib With or Without Brain Radiotherapy in ALK ‐Positive Non‐Small Cell Lung Cancer with Brain Metastases: A Real‐World Multicenter Study from Vietnam},
  journal = {Thoracic Cancer},
  year = {2026},
  doi = {10.1111/1759-7714.70325}
}
Kostenlos starten →